RCM241018P17500
- 4.80
- 0.000.00%
R1 RCM Newsroom
Truist Financial Maintains R1 RCM(RCM.US) With Hold Rating
Truist Financial Releases a Hold Rating on R1 RCM (RCM)
R1 RCM Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on R1 RCM, Maintains $14.3 Price Target
Hold Rating Affirmed for R1 RCM Amidst Revenue Forecast Adjustment and Pending Acquisition
Hold Rating on R1 RCM Amidst Cyberattack Impact and Revenue Delays
R1 RCM Analyst Ratings
Truist Adjusts Price Target on R1 RCM to $14.30 From $16, Maintains Hold Rating
Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY), R1 RCM (RCM) and Lumos Pharma (LUMO)
R1 RCM Price Target Cut to $14.30/Share From $20.00 by TD Cowen
R1 RCM Analyst Ratings
Citigroup Downgrades R1 RCM to Neutral From Buy, Price Target Is $14.30
Citi Downgrades R1 RCM(RCM.US) to Hold Rating, Cuts Target Price to $14.3
TD Cowen Downgrades R1 RCM(RCM.US) to Hold Rating, Cuts Target Price to $14.3
R1 RCM Acquisition Valuation Justifies Hold Rating: Analyst Charles Rhyee's Report Summary
Maintaining Hold Rating on R1 RCM Amid Pending Acquisition by TowerBrook and CD&R
A Quick Look at Today's Ratings for R1 RCM(RCM.US), With a Forecast Between $14.3 to $14.3
Analysts Offer Insights on Healthcare Companies: R1 RCM (RCM) and Walgreens Boots Alliance (WBA)
R1 RCM Analyst Ratings
Maintaining Hold on R1 RCM Amid Acquisition by TowerBrook and CD&R